Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (408)	10/8/2003 10:42:35 PM
From: Jibacoa	Read Replies (3) \| Respond to of 3722

Hi Marc, Yes, AVGN was able to close today above its resistance from the September 15-September 16 double top at the 5.85 level. Although there were some down ticks in the last two minutes of trading, it was able to close near its intra-day H of 6.39 as it continued its up-move for a second day in a roll.(Today's C was 6.32) The averages have remained in the right sequence since the present run started on August 21 from the 3.60 level. The September 9 up-gap was never closed and it has made a double bottom at the 5 level (September 22- September 29) The PSML data on AVGN at present: 6.32 5.84 5.50 & 4.79 The stock still needs to close above its December 18 H of 6.69 before it can test its heavier resistance at the 8 level. As you may recall, December 9 & December 10 were some important trading days for AVGN. On December 9 the stock opened at 10 (that was a 0.60 up-gap from the C on Dec.6 )and its intra-day H was 10.33, but the stock closed the up-gap that same day and the volume was heavy on the downside that afternoon, closing at 7.75 (the intra-day L was 7.25) The next day, December 10 the stock continued its down-move closing at 6.26 (the intra-day L was 6.05) From its December 9 H the stock continued on a down-trend that carried it to its February 28 L at the 2 level.After the April double-bottom at the 2.70 level, the stock was able to start ist May rally that carried it to its June 3 H at 4.90. siliconinvestor.com siliconinvestor.com As you said, they plan to submit an IND for their AAV vector to deliver the gene for AADC directly to the striatum, which theoretically would enable a better control of the level of dopamine in the brain by regulating how much L dopa is taken. Although Parkinson's disease is pretty prevalent,I don't know how well this invasive, "pro-drug" approach will be largely accepted. AVGN reportedly has around $4.90 in cash/share, which should be enough to carry it for 3 years at its present burn rate.The short position is less than 1% of the float.The insiders reportedly hold around 2% and institutions around 49%. Bernard